CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 414 · Search date 2026-07-17 · Methodology v0.6

Lactiplantibacillus plantarum HAC01,
does it really help with Reduced postprandial glucose rise in adults with prediabetes?

30-Second Summary
C
Evidence Grade C · 54 · Safety caution
HAC01 has a short-term postprandial-glucose signal, not evidence of diabetes treatment
What the
research shows
HAC01 lowered two-hour postprandial glucose and HbA1c in an eight-week RCT of 40 adults with impaired glucose tolerance, but fasting glucose, insulin, and HOMA-IR were not significant. One strain, one trial, and surrogate endpoints support C with 54 points.
What the
ads claim
Marketing can frame it as a 'blood-sugar probiotic,' a 'diabetes probiotic,' or a single solution for both gut and glucose health. The evidence is limited to short-term laboratory values in a subgroup with prediabetes, not diabetes treatment, medication replacement, or complication prevention.
*

Useful facts when choosing a product

  • The Korean individually recognized ingredient number is 2022-21, with a recognized intake of HAC01 at 4×10^9 CFU/day.
  • The pivotal RCT used the same 4×10^9 CFU/day in one daily capsule.
  • Korean combination products for glucose and gut health are marketed, but evidence for other probiotics or added ingredients must be separated from the HAC01 glucose evidence.
  • The Korean regulator advises consultation or caution for people with disease or medication use, allergic conditions or short-bowel syndrome, infants and children, and pregnancy or lactation.
Gap Measurement · Verdict 414 · C 54
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The Oh 2021 RCT randomized 40 adults with impaired glucose tolerance to HAC01 at 4×10^9 CFU/day or placebo for eight weeks. Compared with placebo, HAC01 significantly reduced two-hour glucose during a 75 g oral glucose-tolerance test and HbA1c, while fasting glucose, insulin, HOMA-IR, QUICKI, microbiota composition, and fecal short-chain fatty acids were not significant. The trial received government research funding, but no independent replication of HAC01 efficacy in humans was identified.

02

Why this is classified as C (54)

A positive RCT with a prespecified postprandial endpoint exists, but it is an eight-week, 40-person, single-strain, single-trial surrogate study, supporting C with 54 points.

Counterpoint. A human signal for two-hour glucose in adults with prediabetes remains. The judgment applies only to HAC01 at a matching dose and does not extend to diabetes treatment or the entire L. plantarum species.

Rejudgment record. New verdict — Positive postprandial-glucose and HbA1c surrogates in one eight-week, 40-person strain-specific RCT, but null fasting glucose and insulin markers and no independent replication

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Oh MR et al. 2021Randomized double-blind placebo-controlled trial40National Research Foundation of Korea and government grantTwo-hour glucose during a 75 g OGTT, HbA1c, fasting glucose, and insulinTwo-hour glucose and HbA1c improved, while fasting glucose, insulin, HOMA-IR, and QUICKI were not significant.Key
MFDS individually recognized ingredient 2022-21Regulatory ingredient informationNot applicableRecognized function, intake, and precautionsRegistered for helping suppress the postprandial glucose rise at 4×10^9 CFU/day.Product information
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-17).

Oh MR, Jang HY, Lee SY, Jung SJ, Chae SW, Lee SO, Park BH. Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2021;13(7):2337. PMID: 34371847. DOI: 10.3390/nu13072337.
checked
Ministry of Food and Drug Safety. Lactiplantibacillus plantarum HAC01 Probiotics, individually recognized ingredient 2022-21. May 26, 2022. No PMID or DOI.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Lactiplantibacillus plantarum HAC01 x reduced postprandial glucose rise in adults with prediabetes Evidence Grade C card
[Chamgap] Lactiplantibacillus plantarum HAC01 x reduced postprandial glucose rise in adults with prediabetes — Evidence Grade C·54. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/lactiplantibacillus-plantarum-hac01-postprandial-glucose/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.